N Z Vet J
Other integrated safety analyses have reported similar IRs of VTE in AA and AD, including baricitinib in AD (IR, 0.09/100 PY)32 and AA (IR, 0.1/100 PY),24 abrocitinib in AD (IR, 0.3/100 PY),33 and upadacitinib in AD (IRs, 0.3/100 PY [15mg], 0.2/100 PY [30mg]).25 EMA safety recommendations for JAK inhibitors (tofacitinib, baricitinib, upadacitinib, abrocitinib, filgotinib) do not include ritlecitinib.33 Additional long-term data are needed to assess VTE risk with selective JAK3/TEC inhibition in AA.25 Neuroaudiological events In chronic preclinical toxicology studies in dogs, reversible axonal dystrophy in the cerebellum was observed with ritlecitinib at exposures 7.4 times the approved human dose (50mg).25 At 33 times this dose, axonal dystrophy caused reversible hearing loss and alterations in brainstem auditory evoked potential (BAEP) waveforms
Indeed, it was demonstrated that heterodimerization of 1-cysPrx with GSH-saturated GSTP results in S -glutathionylation of the oxidized cysteine in 1-cysPrx followed by subsequent spontaneous reduction of the mixed disulfide and restoration of enzymatic activity (Manevich et al., 2004)
Properly formulated DSIP nasal spray is stable for several months at temperatures between 5C-15C
